Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different Mutations.

Colombo, Marika; Marabese, Mirko; Vargiu, Giulia; Broggini, Massimo; Caiola, Elisa

Colombo, Marika; Marabese, Mirko; Vargiu, Giulia; Broggini, Massimo; Caiola, Elisa.

Afiliação

Colombo M; Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Marabese M; Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Vargiu G; Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Broggini M; Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Caiola E; Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.

Front Oncol ; 10: 532292, 2020.

Article em En | MEDLINE | ID: mdl-33194590

Palavras-chave

3D culture (three-dimensional spheroids); KRAS; Ralimetinib; SMAC mimetic compounds; combination therapeutics; drug library in vitro screening; liver kinase B1; non-small-cell lung cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article